Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Instagram
Telegram
LinkedIn

Barcha huquqlar himoyalangan.

Foydalanish shartlari

Bosh sahifa
Bozorlar
Skriner
Yangiliklar
Biz haqimizda

LFCR - Lifecore Biomedical, Inc. So'nggi... | Finranks

Home

LFCR

L

Lifecore Biomedical, Inc. (LFCR)

NMS – Real vaqt narxi. Valyuta: USD

3.66

-0.21 (-5.43%)

Yopilishda: Mar 27, 2026, 4:00 PM EDT

3.66

0.00 (0.00%)

Bozordan keyin: Mar 27, 2026, 4:10 PM EDT

Umumiy
Yangiliklar
Grafik
Hisobotlar
Dividendlar
Kutilma
Egalik
Profil

Lifecore Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Lifecore Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

CHASKA, Minn., March 26, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”) a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced that effective on March 25, 2026, Lifecore granted a restricted stock unit (“RSU”) award with respect to 18,500 shares of its common stock under Lifecore's Equity Inducement Plan, as amended (the “Inducement Plan”) to a newly hired employee of Lifecore.

Lifecore Biomedical Signs Two New Agreements with Existing U.S. Biopharmaceutical Customer

Lifecore Biomedical Signs Two New Agreements with Existing U.S. Biopharmaceutical Customer

-- Site Transfer Agreement for the Manufacture of Commercially Marketed Product -- -- Second Agreement Supports the Expansion of Product Commercially Manufactured at Lifecore to a New Delivery System -- -- Fourth Commercial Site Transfer Agreement Win in Five Months -- -- Both Programs are Additive to Lifecore's High-Value, Late-Stage Pipeline and Expected to Contribute to 2028 Commercial Revenue -- CHASKA, Minn., March 26, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR ) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced that it has signed two CDMO manufacturing service agreements with an existing U.S. biopharmaceutical customer.

Lifecore Biomedical Signs Commercial Site Transfer Agreement with Leading Medical Aesthetics Company

Lifecore Biomedical Signs Commercial Site Transfer Agreement with Leading Medical Aesthetics Company

-- Agreement for the Commercial Manufacture of Established, Approved Aesthetic Product -- -- Third Commercial Site Transfer Agreement Win in Five Months -- -- Program Expected to Generate Commercial Revenue in 24 Months, Contributing to 2029 Revenue CAGR -- CHASKA, Minn., March 23, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR ) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced that it has signed a CDMO manufacturing services agreement with a new aesthetics customer for an established, market-approved product.

Lifecore Biomedical Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Lifecore Biomedical Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

SAN DIEGO, March 16, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Lifecore Biomedical, Inc. The investigation focuses on Lifecore Biomedical executive officers and whether investor losses may be recovered under federal securities laws.

Lifecore Biomedical, Inc. (LFCR) Q4 2025 Earnings Call Transcript

Lifecore Biomedical, Inc. (LFCR) Q4 2025 Earnings Call Transcript

Lifecore Biomedical, Inc. (LFCR) Q4 2025 Earnings Call Transcript

Lifecore Biomedical Reports Financial Results for the Fourth Quarter and Transition Period Ended December 31, 2025, and Provides Corporate Update

Lifecore Biomedical Reports Financial Results for the Fourth Quarter and Transition Period Ended December 31, 2025, and Provides Corporate Update

-- Recorded Fourth Quarter Revenues of $35.7 Million and Transition Period Revenues of $75.5 Million -- -- Multiple New Programs Signed in Fourth Quarter 2025 Including Two Commercial Site Transfer Programs, for Total of Five New Programs in 2025 Transition Period -- -- Organizational Initiatives Drive Further Improvement in Margins -- Conference Call Today at 8:30am ET CHASKA, Minn., March 16, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore” or the “Company”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced strong results for the fourth quarter and transition period ended December 31, 2025.

Lifecore Biomedical to Participate in 6th Annual KeyBanc Capital Markets Healthcare Virtual Forum

Lifecore Biomedical to Participate in 6th Annual KeyBanc Capital Markets Healthcare Virtual Forum

CHASKA, Minn., March 10, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced that the company will participate in the upcoming KeyBanc Capital Markets Healthcare Virtual Forum.

Videolar

No Data

There is no data to display

Press-relizlar

Lifecore Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Lifecore Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

CHASKA, Minn., March 26, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”) a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced that effective on March 25, 2026, Lifecore granted a restricted stock unit (“RSU”) award with respect to 18,500 shares of its common stock under Lifecore's Equity Inducement Plan, as amended (the “Inducement Plan”) to a newly hired employee of Lifecore.

Lifecore Biomedical Signs Two New Agreements with Existing U.S. Biopharmaceutical Customer

Lifecore Biomedical Signs Two New Agreements with Existing U.S. Biopharmaceutical Customer

-- Site Transfer Agreement for the Manufacture of Commercially Marketed Product -- -- Second Agreement Supports the Expansion of Product Commercially Manufactured at Lifecore to a New Delivery System -- -- Fourth Commercial Site Transfer Agreement Win in Five Months -- -- Both Programs are Additive to Lifecore's High-Value, Late-Stage Pipeline and Expected to Contribute to 2028 Commercial Revenue -- CHASKA, Minn., March 26, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR ) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced that it has signed two CDMO manufacturing service agreements with an existing U.S. biopharmaceutical customer.

Lifecore Biomedical Signs Commercial Site Transfer Agreement with Leading Medical Aesthetics Company

Lifecore Biomedical Signs Commercial Site Transfer Agreement with Leading Medical Aesthetics Company

-- Agreement for the Commercial Manufacture of Established, Approved Aesthetic Product -- -- Third Commercial Site Transfer Agreement Win in Five Months -- -- Program Expected to Generate Commercial Revenue in 24 Months, Contributing to 2029 Revenue CAGR -- CHASKA, Minn., March 23, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR ) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced that it has signed a CDMO manufacturing services agreement with a new aesthetics customer for an established, market-approved product.

Lifecore Biomedical Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Lifecore Biomedical Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

SAN DIEGO, March 16, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Lifecore Biomedical, Inc. The investigation focuses on Lifecore Biomedical executive officers and whether investor losses may be recovered under federal securities laws.